PerkinElmer (PKI) PT Raised to $175 at Stifel Following EPS and BioLegend Deal

Go back to PerkinElmer (PKI) PT Raised to $175 at Stifel Following EPS and BioLegend Deal

PerkinElmer (PKI) Tops Q2 EPS by 41c, Offers Q3 and FY Guidance

July 26, 2021 6:36 AM EDT

PerkinElmer (NYSE: PKI) reported Q2 EPS of $2.83, $0.41 better than the analyst estimate of $2.42. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.12 billion.

GUIDANCE:

PerkinElmer sees Q3 2021 EPS of $1.62, versus the consensus of $1.75. PerkinElmer sees Q3 2021 revenue... More

PerkinElmer (PKI) Acquires BioLegend for $5.25B

July 26, 2021 6:30 AM EDT

PerkinElmer (NYSE: PKI) announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments.

BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing. The transaction will be the largest in PerkinElmers history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary... More

PerkinElmer (PKI) Declares $0.07 Quarterly Dividend; 0.2% Yield

July 23, 2021 4:15 PM EDT

PerkinElmer (NYSE: PKI) declared a quarterly dividend of $0.07 per share, or $0.28 annualized.

The dividend will be payable on November 12, 2021, to stockholders of record on October 22, 2021, with an ex-dividend date of October 21, 2021.

The annual yield on the dividend is 0.2 percent.

For a dividend... More